Cemiplimab Extends Disease-Free Time in Skin Cancer Post-Op

Patients with local or regional cutaneous squamous cell carcinoma are randomly assigned to receive cemiplimab or placebo post-op.
Medscape Medical News

source https://www.medscape.com/viewarticle/cemiplimab-extends-disease-free-time-skin-cancer-post-op-2025a1000lu7?src=rss